Braveheart Bio Deal History & Licensing Activity
Braveheart Bio is a life sciences. Over the past three years, Braveheart Bio has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Small Molecules
Focus Area
Cardiovascular
Braveheart Bio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Braveheart Bio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| myosin inhibitor | Braveheart | Small Molecules | Unknown | collaboration | Jul 2025 |
| myosin inhibitor | Hengrui | Small Molecules | Phase 3 | collaboration | Jul 2025 |
Braveheart Bio Pipeline Focus
Therapeutic areas and modalities where Braveheart Bio is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Braveheart Bio Strategic Signals
Key indicators of Braveheart Bio's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Braveheart Bio's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Braveheart Bio Licensing & Deal Activity
Braveheart Bio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Braveheart Bio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Braveheart Bio include Cardiovascular (4 deals and trials). In terms of modality, Braveheart Bio has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Braveheart Bio and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Braveheart Bio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.